Germany, SwitzerlandSwitzerland

Unitectra wins European Biotechnica Award

12.10.2011

The Swiss technology transfer organisation Unitectra is the winner of the European Biotechnica Award 2011. The specialist for technology transfer received the award from hands of Lower Saxony's Minister for Economy Jörg Bode. The CEO of the Swiss Biotech Association, Domenico Alexakis, described Unitectra as a "global top performer in its class." Since its foundation in 1996, the non profit organisation, which is owned by the Universities of Bern and Zurich, negotiated more than 6,300 research cooperations between academia and industry. This resulted in 63 start up companies and creating more than 1,000 jobs so far.
The European BIOTECHNICA Award was presented by Deutsche Messe AG as part of a festive evening event on the first day of Biotechnica. The fair takes place from October 11 to 13 in Hanover. This year for the first time, a technology transfer organisation has won the prize. Compared to previous years, Deutsche Messe introduced a number of changes for the Biotechnica Award. The most important thing: So far, only European biotech companies were eligible for the award. From 2011 on the focus can vary in each round. This year, the Award targeted technology transfer organisations. A decision which was welcomed by the Chairman of the Jury Karsten Henco: "The lack of commercial perspective in academic research institutes is something that has been a concern to me for a long time." Together with the other members of the jury the biotech investor Henco had made a short list of five finalists. Unlike in previous years, this year there was only one prize and there is no money in it. Herbert Reutimann, managing director and co-founder of Unitectra, was nevertheless happy with the award. "For us, this is a valuable recognition for the work we have done in the past 15 years."

SwitzerlandSwitzerland

21.02.2012

Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...

SwitzerlandSwitzerland

26.01.2012

Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....

SwitzerlandSwitzerland

23.01.2012

Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...

SwitzerlandSwitzerland

19.12.2011

Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...

SwitzerlandSwitzerland

17.12.2011

Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...

SwitzerlandSwitzerland

14.12.2011

Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...

SwitzerlandSwitzerland

14.12.2011

Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody,...

SwitzerlandSwitzerland

22.11.2011

Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...

SwitzerlandSwitzerland

16.11.2011

Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/1/article/unitectra-wins-european-biotechnica-award.html

Image Gallery

Stock list

All quotes

TOP

  • CYTOS (CH)0.23 CHF53.3%
  • BAVARIAN NORDIC (D)14.56 EUR10.3%
  • CO.DON (D)3.40 EUR9.7%

FLOP

  • WILEX (D)0.88 EUR-15.4%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • FLAMEL TECHNOLOGIES (F)11.01 USD-13.5%

TOP

  • CO.DON (D)3.40 EUR91.0%
  • WILEX (D)0.88 EUR51.7%
  • BIOTECH PHARMACON (N)17.50 NOK50.9%

FLOP

  • CYTOS (CH)0.23 CHF-92.0%
  • BIONOR PHARMA (N)2.11 NOK-47.9%
  • GW PHARMACEUTICALS (UK)219.50 GBP-46.5%

TOP

  • SILENCE THERAPEUTICS (UK)255.00 GBP5900.0%
  • IXICO (UK)69.50 GBP776.4%
  • PLETHORA (UK)11.00 GBP609.7%

FLOP

  • CYTOS (CH)0.23 CHF-94.7%
  • EVOCUTIS (UK)0.22 GBP-92.9%
  • AGENNIX (D)0.04 EUR-78.9%

No liability assumed, Date: 15.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper